BPC-157 + TB-500 + GHK-Cu + KPV

Why these are combined

Adds KPV, an alpha-MSH-derived tripeptide that suppresses IL-1beta, IL-6 and TNF-alpha, to the base three-peptide recovery stack. The idea is to calm inflammation while the other three drive repair. Nobody has tested all four together.

Mechanism & pharmacokinetics

KPV adds a fourth, again mechanistically distinct pathway: it's an alpha-MSH-derived tripeptide that works through melanocortin-receptor signaling and direct suppression of NF-kB-driven cytokine production (IL-1beta, IL-6, TNF-alpha), independent of the growth-factor, actin, and collagen-remodeling pathways the other three use. Like BPC-157 and GHK-Cu, KPV clears from plasma quickly and is dosed frequently in community protocols. The name 'KLOW' is generally explained in community sources as 'K(PV) + (G)LOW' — the GLOW stack with KPV added, rather than a literal per-letter acronym of all four ingredients. Combining four unstudied-together compounds compounds the uncertainty rather than resolving it: there is no data on the four-way combination, only individual-peptide and at-most-three-peptide reasoning stacked on top of each other.

Citations

• KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARgamma signaling — An et al. 2026
• Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers — Cheng et al. 2026

Typical community protocol

BPC-157 250-500 mcg daily, TB-500 2-4 mg weekly, GHK-Cu 200-300 mcg daily, KPV 100-300 mcg daily (occasionally intranasal). Often run 8-16 weeks for injury or post-surgical recovery.

Safety notes